These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22206665)

  • 1. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
    Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
    Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistant breast cancer cells overexpress ETS1 gene.
    Kars MD; Işeri OD; Gündüz U
    Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.
    Kato T; Fujita Y; Nakane K; Mizutani K; Terazawa R; Ehara H; Kanimoto Y; Kojima T; Nozawa Y; Deguchi T; Ito M
    Cytokine; 2013 Oct; 64(1):251-7. PubMed ID: 23876400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
    Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
    Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
    Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
    Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
    Fujita Y; Kojima K; Ohhashi R; Hamada N; Nozawa Y; Kitamoto A; Sato A; Kondo S; Kojima T; Deguchi T; Ito M
    J Biol Chem; 2010 Jun; 285(25):19076-84. PubMed ID: 20406806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
    Tao W; Shi JF; Zhang Q; Xue B; Sun YJ; Li CJ
    Biomed Pharmacother; 2013 Apr; 67(3):197-202. PubMed ID: 23478574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells.
    Flynn V; Ramanitharan A; Moparty K; Davis R; Sikka S; Agrawal KC; Abdel-Mageed AB
    Int J Oncol; 2003 Aug; 23(2):317-23. PubMed ID: 12851680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
    Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
    Hasegawa K; Ishikawa K; Kawai S; Torii Y; Kawamura K; Kato R; Tsukada K; Udagawa Y
    Oncol Rep; 2013 Dec; 30(6):2937-44. PubMed ID: 24100466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of the Ets1 proto-oncogene.
    Dittmer J
    Mol Cancer; 2003 Aug; 2():29. PubMed ID: 12971829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
    Lee JT; Steelman LS; McCubrey JA
    Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.